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Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder
manifesting as lifelong deficits in social communication and interaction, as well as
restricted repetitive behaviors, interests and activities. While there are no specific
pharmacological or other physical treatments for autism, in recent years repetitive
Transcranial Magnetic Stimulation (rTMS), a technique for non-invasive neuromodulation,
has attracted interest due to potential therapeutic value. Here we report the results of a
systematic literature review and meta-analysis on the use of rTMS to treat ASD.
Methods: We performed a systematic literature search on PubMed, Web of Science,
Science Direct, Bielefeld Academic Search, and Educational Resources Information
Clearinghouse. Search terms reflected diagnoses and treatment modalities of interest.
Studies reporting use of rTMS to treat core ASD or cognitive symptoms in ASD were
eligible. Two researchers performed article selection and data extraction independently,
according to PRISMA guidelines. Changes in ASD clinical scores or in cognitive
performance were the main outcomes. Random effects meta-analysis models were
performed.
Results: We found 23 eligible reports, comprising 4 case-reports, 7 non-controlled
clinical trials, and 12 controlled clinical trials, comparing the effects of real TMS with
waiting-list controls (n = 6) or sham-treatment (n = 6). Meta-analyses showed a
significant, but moderate, effect on repetitive and stereotyped behaviors, social behavior,
and number of errors in executive function tasks, but not other outcomes. Most studies
had a moderate to high risk of bias, mostly due to lack of subject- and evaluator-blinding
to treatment allocation. Only 5 studies reported stability of these gains for periods of up
6 months, with descriptions that improvements were sustained over time.
Conclusions: Existing evidence supports that TMS could be useful to treat some
dimensions of ASD. However, such evidence must be regarded with care, as most
studies did not adequately control for placebo effects. Moreover, little is known regarding
the most effective stimulation parameters, targets, and schedules. There is an urgent
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need for further randomized, double-blind, sham-controlled trials, with adequate
follow-up periods, to test the efficacy of transcranial magnetic stimulation to treat these
disorders. Available evidencemust be regarded as preliminary and insufficient, at present,
to support offering TMS to treat ASD.
Keywords: autism, Asperger’s, non-invasive brain stimulation, TMS, rTMS, TBS, meta-analysis
INTRODUCTION
Rationale
Autism Spectrum Disorder (ASD) is a diagnostic category that
encompasses a group of neurodevelopmental disorders with
varying degrees of severity, sharing a common syndromatic
core dyad of significant deficits in social communication and
interaction, and repetitive behaviors with restricted interests and
activities (American Psychiatric Association, 2013; Volkmar and
McPartland, 2014). Deficits in communication can present as
absent or severely impaired language development, and restricted
interests can vary from extremely stereotyped, non-functional
repetitive behavior, to milder forms of over-involvement or
over-investment in a limited span of interests and activities
(Volkmar and McPartland, 2014). Other features that are
frequently associated include cognitive delay, epilepsy, and
motor clumsiness, as well as significant psychiatric co-morbidity,
such as obsessive-compulsive disorder, affective disorders, and
attention deficit and hyperactivity disorder (Stahlberg et al.,
2004; Russell et al., 2005; Hutton et al., 2008; Mouridsen et al.,
2008). Furthermore, ASD patients are impaired in a number
of neuropsychological tasks, namely theory of mind tests and
tasks depending on executive functions such as workingmemory,
prepotent response inhibition or interference control (Kana et al.,
2015; Wallace et al., 2015; Geurts and Lever, 2017). ASD is a
lifelong disorder, and most patients remain severely impaired in
terms of psychosocial functioning throughout their adult lives
(Billstedt et al., 2005; Farley et al., 2009). Currently there are
important limitations in the treatment of ASD. Pharmacological
treatment is only indicated for psychiatric comorbidity and has
no measurable impact on ASD core manifestations. Available
non-pharmacological interventions, on the other hand, are
generally expensive, time-consuming and have modest results
(Buescher et al., 2014).
In more recent years the availability of non-invasive
neuromodulation techniques has raised hope that they might
prove an effective tool in the treatment of ASD core
manifestations (Oberman and Enticott, 2015). Transcranial
Magnetic Stimulation (TMS) is a non-invasive neuromodulation
technique that has attracted particular interest. TMS uses
electromagnetic induction to generate transient, localized
electrical fields in the brain cortex, causing depolarization and
firing of local neurons (Hallett, 2000). Repetitive TMS (rTMS)
Abbreviations: ASD, autism spectrum disorders; CI, confidence interval; cTBS,
continuous theta burst stimulation; DLPFC, dorsolateral prefrontal cortex;
DMPFC, dorsomedial prefrontal cortex; iTBS, intermittent theta burst stimulation;
rTMS, repetitive transcranial magnetic stimulation; TMS, transcranial magnetic
stimulation.
delivers patterns of multiple TMS pulses over a chosen brain
area, at frequencies that typically vary between 0.5Hz and 20Hz
(Pascual-Leone et al., 1999). At low frequencies, rTMS results
in long-term suppression of cortical excitability on the target
cortical tissue, while at frequencies above 5Hz, rTMS mostly
induces long-term facilitation of cortical excitability (Pascual-
Leone et al., 1998). These effects, however, are subject to
significant inter-individual variability (Maeda et al., 2000). An
alternative modality of rTMS delivery is Theta-burst Stimulation
(TBS), where TMS pulses are delivered in 50Hz 3-pulse
bursts, at 200ms intervals (i.e., with a 5Hz burst frequency).
Continuous TBS (cTBS) suppresses cortical excitability, while
intermittent TBS (iTBS), where TBS is delivered for 2 s every
10 s, has facilitatory effects on the cortex (Huang et al.,
2005).
Use of TMS in humans is generally safe and well tolerated,
and rTMS has received formal approval for the treatment of
drug-resistant Major Depression (Rossi et al., 2009). For these
reasons, TMS has become an attractive treatment option in
ASD, stimulating interest in particular among ASD patients and
their parents, who are characteristically attentive to innovative
treatments (Levy and Hyman, 2005). Unfortunately, it remains
unsettled whether there is indeed a place for rTMS in the
treatment arsenal for ASD. In a narrative review published
in 2016, Oberman et al. (2016) found 12 studies and three
case-reports describing the use of rTMS protocols in ASD
with therapeutic intent (Oberman et al., 2016). Stimulation
parameters and targets varied widely across studies, and most
of them were open-label. The authors concluded that evidence
for improvement of specific ASD-related behavioral symptoms
resulting from rTMS applied to specific cortical regions, while
encouraging, was limited. In fact, results at the individual level
were mixed, and large-scale controlled trials were lacking. Here
we describe an update of this work, 3 years after its initial online
publication. In further development of prior methods (Oberman
et al., 2016) we conducted a systematic review of the literature,
for published reports on the therapeutic use of rTMS in patients
with ASD. Furthermore, we performed meta-analyses of the data
in these reports, thus offering the first estimation of pooled
effects sizes for the effects of TMS on several clinical dimensions
of ASD.
Objectives
While there are clinical programs offering rTMS to treat ASD
symptoms, the evidence-base sustaining efficacy and safety in
this context remains unclear. Moreover, the optimal stimulation
parameters and brain targets remain undefined. Here we
conducted a systematic literature review and meta-analysis to
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explore available data regarding the therapeutic use of rTMS
for ASD.
Research Question
We were interested in understanding whether the published
literature supports use of TMS for amelioration of core-




We conducted a systematic review of the literature with
meta-analyses of studies reporting quantitative data, separated
according to the outcome of interest.
Participants, Interventions, Comparators
We were interested in reviewing studies conducted in patients
with any ASD, regardless of age or gender. Given the limitations
in the available literature, we were interested in any clinical
trial, regardless of design, as well as case-studies or case-series,
reporting the effects of rTMS on ASD core symptoms and/or
cognitive performance.
Systematic Review Protocol
The systematic review was conducted according to a protocol
following PRISMA guidelines.
Search Strategy
The search was performed on PubMed, Web of Science,
BASE (Bielefeld Academic Search), ERIC (educational resources
information clearinghouse) and Science Direct, between June
2016 and January 2018. Search terms reflected the diagnoses of
interest (Autism, Autism Spectrum Disorders, Asperger) and the
interventions of interest (Transcranial, TMS, rTMS, TBS).
After eliminating duplicates, two researchers reviewed the
list of articles separately, selecting eligible reports according
to PRISMA procedures. Articles in English, French, German,
Portuguese or Spanish were considered, regardless of publication
date or country of origin. Only full articles published in
peer-review journals were considered. Literature reviews were
excluded, but were screened for additional references, as were
reference lists of eligible articles.
Data Sources, Studies Sections, and Data
Extraction
Two researchers extracted data separately according to PRISMA
guidelines. From each eligible paper, whenever possible we
extracted information separately for patients included in
the active treatment and those in the control intervention
arm, namely author, publication year and journal, number of
participants, gender distribution, mean age, mean intelligence
quotient, number of dropouts, type of TMS stimulation,
stimulation parameters and target, stimulation schedule,
behavioral outcome measures, cognitive outcome measures,
number and nature of any reported side-effects, follow-up
period duration, additional information. Risk of selection bias,
performance bias, attrition bias and detection bias were also
registered according to Cochrane guidelines (Higgins and Green,
2006).
For each outcome variable from each eligible study, depending
on what was reported in the original paper, we extracted pre-
treatment and post-treatment mean and standard deviation,
F-value from Analysis of Variance tests, and/or Cohen’s d
estimates. If reported we also extracted mean change from
baseline, standard deviation of this measure and/or paired t-
test t-values. Data were extracted either directly from the text
and tables or extrapolated from figures. In the latter situation
values (mean and standard deviation or standard error of the
mean) were extracted using Adobe Acrobat Reader measurement
tools. To account for measurement error, each value from each
figure was measured five times, and the mean value computed.
In cases where data included in the original manuscript were
insufficient, we contacted the corresponding author to request
further information. Data is described in the manuscript as mean
± standard deviation. Original data supporting the conclusions
of this manuscript will be made available by the authors, without
undue reservation, to any qualified researcher.
Data Analysis
To estimate effect-sizes we computed Hedges g
for each study, using Meta-essentials workbooks
( http://www.erim.eur.nl/research%7D-support/meta-essentials/).
For controlled studies, computations were conducted using one
of the following, according to what was reported: post-treatment
means and standard deviations of both the active treatment
and the control intervention groups, F-values from Analysis of
Variance tests, or Cohen’s d estimates. When, instead of raw
outcome data, authors reported mean change from baseline,
within-group standard deviation for the outcome measures
was estimated using σ = σD√
2(1−ρ)
, where σD stands for
the standard deviation of the difference relative to baseline,
and ρ for the correlation between pre- and post-treatment
scores (Borenstein et al., 2009a). For non-controlled studies
a repeated measures approach was adopted for calculation of
Hedges g, with use of either pre- and post-treatment means
and standard deviations, or mean change from baseline, the
respective standard deviation (SD2D) and correlation coefficient
between pre- and post-treatment scores. When the latter was
not provided we computed the correlation coefficient using the
formulas r = SDpre
2 + SDpost2 −SD2D






where t2RM is the pre-post paired t-test value, Mpre is the pre-
TMS mean score and Mpost the post-TMS mean score (Morris
and DeShon, 2002). When reported data were insufficient for
this computation, r-values were extrapolated from other papers
with similar clinical populations, or, when this was not possible,
from published data on the test-retest reliability of that specific
measure.
Where a sufficient number of studies were available, results
for relevant symptom dimensions or cognitive functions were
included in random effects model meta-analyses, separately for
controlled and uncontrolled studies. Controlled studies that
did not report outcome data for the control group regarding
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a specific clinical outcome dimension were entered in the
corresponding meta-analysis of uncontrolled studies. For each
meta-analysis, the decision to include any given study was
essentially determined by the availability of sufficient quantitative
data reporting treatment effects on the clinical dimension of
interest. Due to the small number of available studies, study
quality was not considered in the decision of inclusion. Meta-
essentials workbooks 1, 3, and 4 were used to compute bias-
adjusted standardized mean differences (Hedges g, expressed
as 95% confidence intervals−95% CI), as well as combined
effect sizes with hypothesis testing. Individual studies were
weighed according to the inverse variance weighting method,
with an added between-studies variance component based on
the DerSimonian-Laird estimator (Sánchez-Meca and Marín-
Martínez, 2008). Confidence intervals were estimated using the
weighted variance method, as described previously (Sánchez-
Meca and Marín-Martínez, 2008). This approach takes into
account the uncertainty resulting from the need to estimate
heterogeneity variance and within-study variances, resulting in
wider estimated confidence intervals for the combined effect size
in analyses based on small numbers of studies. In the latter
situation, and especially when heterogeneity is high, confidence
intervals may include 0 even when classical z-distribution
confidence intervals would not. To assess heterogeneity of
studies, in each meta-analysis we used Cochrane’s Q-test to
examine the null hypothesis that all studies estimated the
same effect. We further computed I2 to estimate the ratio
of true heterogeneity to total observed variation, and Tau2
(T2) to estimate between-study variance (Higgins et al., 2003).
Publication bias was examined by means of funnel-plots, with
Egger regression and trim-and-fill analysis for estimation of the
adjusted effect size and of missing studies (Borenstein et al.,
2009b).
RESULTS
Study Selection and Characteristics
Figure 1 shows a flow diagram of the process leading to the
identification of 23 eligible papers, using rTMS for therapeutic
purposes in subjects with ASD (refer to Tables 1–3 for individual
study details). Four of these papers were case-reports (Enticott
et al., 2011; Niederhofer, 2012; Cristancho et al., 2014; Avirame
et al., 2017), 7 were non-controlled trials (Sokhadze et al., 2010,
2016, 2017; Casanova et al., 2014;Wang et al., 2016; Abujadi et al.,
2017; Gómez et al., 2017) and the remaining 12 were controlled
trials (Sokhadze et al., 2009, 2012, 2014a,b; Baruth et al., 2010;
Fecteau et al., 2011; Casanova et al., 2012; Enticott et al., 2012,
2014; Panerai et al., 2014; Anninos et al., 2016; Ni et al., 2017).
FIGURE 1 | Article selection flowchart (according to PRISMA Statement).
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Six of the controlled studies used sham rTMS as the control
intervention (Fecteau et al., 2011; Enticott et al., 2012, 2014;
Panerai et al., 2014; Anninos et al., 2016; Ni et al., 2017) while
the remaining 6 compared rTMS-treated patients with wait-list
controls. Three studies recruited exclusively adult subjects to
the experimental arm (Fecteau et al., 2011; Enticott et al., 2014;
Ni et al., 2017), with the remainder focusing predominantly
on children and adolescents. Overall, data were reported from
371 rTMS-treated patients, with a mean age of 15.9 ± 5.2
years, 5 of whom in case-reports (26.4 ± 9.3 years-old) and the
remaining 366 from intervention studies (15.8 ± 5.1 years-old).
The overwhelming majority of studies recruited patients with an
IQ higher than 80. The 4 trials reported in the paper by Panerai
et al. (2014) were all performed on subjects with severe cognitive
impairment, while Abujadi et al. (2017), Baruth et al. (2010),
and Wang et al. (2016) included patients both with and without
cognitive impairment.
One study used a pico-Tesla TMS protocol (Anninos et al.,
2016) while two others used TBS protocols (Abujadi et al.,
2017; Ni et al., 2017). Pico-Tesla TMS is a technology invented
and used by a specific research group (Anninos and Tsagas,
1995). It uses a modified helmet containing up to 122 coils
arranged in several arrays. This allows for delivery of low-
intensity transcranial magnetic stimulation, at the pico-Tesla
level (1 pico-Tesla = 10−12 Tesla), simultaneously to several
brain areas, at frequencies of 2–7Hz (Anninos et al., 2016). The
remaining studies used other, more conventional rTMSmethods.
Most studies targeted stimulation to the dorsolateral prefrontal
cortex (DLPFC), either bilaterally or in the left hemisphere,
using low stimulation frequencies (0.5–1Hz). Ni et al. (2017)
additionally stimulated the posterior superior temporal sulcus
using iTBS, while Fecteau et al. (2011) used 1Hz rTMS to
stimulate the pars triangularis and pars opercularis of the inferior
frontal gyrus, bilaterally. Avirame et al. (2017) and Enticott
et al. (2011, 2014) targeted the dorsal medial prefrontal cortex
(DMPFC) with stimulation frequencies of 5Hz. Panerai et al.
(2014) stimulated the left premotor cortex (and in a subgroup of
patients also the right premotor cortex) at 8Hz, while Enticott
et al. (2012) chose to stimulate the left primary motor cortex
and supplementary motor area with 1Hz rTMS. The pico-
Tesla TMS trial targeted stimulation to the vertex, frontal and
occipital cortex, left and right parietal cortex, and left and right
temporal cortex, at frequencies of 8–13Hz (Anninos et al., 2016).
Treatment schedules also varied widely. While most studies
delivered treatment in weekly or twice-weekly sessions, some
delivered daily sessions for 5–29 days consecutively (Niederhofer,
2012; Cristancho et al., 2014; Enticott et al., 2014; Panerai et al.,
2014; Anninos et al., 2016; Avirame et al., 2017; Gómez et al.,
2017). A limited number of studies used a single session in a
proof of concept approach (Fecteau et al., 2011; Panerai et al.,
2014; Ni et al., 2017). Only two studies used neuronavigation to
guide stimulation of the intended cortical region. All studies used
conventional figure of eight coils, with the exception of Enticott
et al. (2014), where an H-coil was used, and Anninos et al. (2016),
where a specially designed helmet, containing up to 122 coils, was
chosen.
Synthesized Findings and Risk of Bias
Effects on Behavior
Sixteen studies assessed the effects of rTMS on ASD symptoms
or ASD associated behavioral problems. Seven of these studies
were prospective and non-controlled (Sokhadze et al., 2010, 2016,
2017; Casanova et al., 2014; Wang et al., 2016; Abujadi et al.,
2017; Gómez et al., 2017). Data from the study by Gómez et al.
(2017), who used both rTMS and transcranial direct current
stimulation in their sample, could not be used as authors did
not provide separate outcome data for the rTMS intervention.
Two other studies, while reporting a waiting-list control design,
did not provide data for the control group, and were thus
analyzed jointly with non-controlled studies in a pre-post meta-
analysis design (Sokhadze et al., 2009; Baruth et al., 2010). The
remaining seven studies were controlled with either waiting-
list controls (Casanova et al., 2012; Sokhadze et al., 2014a,b),
sham-rTMS (Enticott et al., 2014; Ni et al., 2017), or sham pico-
Tesla TMS (Anninos et al., 2016, 2017). Anninos et al. (2016)
provided only a qualitative description of symptom change in
their treated patients, with no quantitative assessment of change.
In a recently published study from the same research group,
similarly-designed to test the effects of pico-Tesla TMS on
ASD symptoms, and that was not retrieved by our systematic
search strategy (Anninos et al., 2017), clinical improvement was
reported in 6 of 8 children, but described only qualitatively, rather
than quantitavely, and was also not included in the data synthesis.
The different studies assessed the effects of rTMS on one or
more of three behavioral dimensions: restricted and repetitive or
stereotyped behavior; impairments in social behavior; other non-
core ASD-related symptoms, such as hyperactivity or irritability.
The specific instruments used in each study are detailed in
Table 3.
With regards to stereotyped and repetitive behavior, the effects
of rTMSwere measured using the total Repetitive Behavior Scale-
Revised (RBS-R), stereotypy subscale of the Aberrant Behavior
Checklist (ABC), Attention Switching subscale of the Autism
Spectrum Quotient, or compulsion subscale of the Yale-Brown
Obsessive-Compulsive Scale. In all of these scales higher scores
reflect higher symptom severity. Figure 2 shows the forest plot
of the pre-post analysis for 8 non-controlled studies. Three of
these studies included a control group but were included in this
meta-analysis as no outcome data were reported for the control
group (Sokhadze et al., 2009, 2016; Baruth et al., 2010). All of the
eight studies incurred in risk of bias, as none was subject- or rater
blinded, and none used an intent-to-treat approach regarding
dropouts. All but Abujadi et al. (2017), that used iTBS, applied
low-frequency rTMS with stimulus frequencies between 0.5 and
1Hz. Sokhadze et al. (2010) and Sokhadze et al. (2009) targeted
the left DLPFC, while Abujadi et al. (2017) stimulated the right
DLPFC. The remaining five trials chose bilateral stimulation of
the DLPFC. We found a significant combined effect size of−0.52
(95%CI:−0.72 to−0.32; z=−6.17; p< 0.001), with a significant
Cochrane’s Q-test of Heterogeneity (Q = 14.4, p = 0.04), I2-
value of 51.5% and T2 of 0.02. The funnel plot and trim-and-fill
analysis were suggestive of publication bias, with two missing
negative studies and an adjusted effect size of−0.46 (95% CI:
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FIGURE 2 | Effects of rTMS on repetitive and restricted behavior in non-controlled studies. (A) Forest-plot. Dots represent each study, with dot size reflecting study
weight in the model and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its confidence interval
(narrow interval) and its 95% prediction interval (wide interval). The latter gives the range in which, in 95% of the cases, the outcome of a future study will fall, assuming
that the effect sizes of studies are normally distributed. (B) Funnel-plot. There is evidence of significant publication bias. Square-shaped dots represent studies
imputed by trim-and-fill analysis.
−0.67 to −0.25; Figure 2). Egger statistic was also significant
(intercept = −3.2, 95%CI: −5.5 to −0.9; t = −3.3, p = 0.02),
suggesting a significant bias.
Figure 3 shows the forest plot of 5 controlled studies that
assessed the effects of rTMS on stereotyped and repetitive
behavior. Only one of these studies was randomized, sham-
controlled and double-blind (Enticott et al., 2014). The remaining
incurred in risk of bias due to lack of randomized treatment
attribution or adequate blinding. Moreover, only Enticott et al.
(2014) and Ni et al. (2017) adopted sham-controlled designs,
the remainder comparing the active TMS arm with wait-list
condition. Enticott et al. (2014) stimulated the DMPFC bilaterally
at 5Hz, using a H-coil, while Ni et al. (2017) used iTBS to
stimulate both right and left DLPFC. The remaining three
studies also stimulated the DLPFC bilaterally with 1Hz rTMS.
A combined effect size of −0.5 was found (95% CI: −0.85 to
−0.16; z = −4.1; p < 0.001) with a non-significant Cochrane’s
Q-test (Q = 4.4, p = 0.4), I2-value of 9% and T2 of 0.01.
The funnel plot for this combined effect size estimation was
asymmetrical, and the trim-and-fill analysis was suggestive of
publication bias, with two missing studies and an adjusted
effect size of −0.4 (95% CI: −0.71 to −0.1; Figure 3). Egger
statistic was significant (intercept = −3.5, 95%CI: −5.7 to −1.2;
t =−4.3, p= 0.02).
The effects of rTMS on the social behavior were computed
based on the scores of the Social Responsiveness Scale (SRS),
Lethargy and Social Withdrawal subscale of the ABC, or Social
Relatedness subscale of the Ritvo Autism-Aspergers Diagnostic
Scale (RAADS). Figure 4 summarizes pre-post design studies,
comprising 7 studies, all by the same research group. Three of
these studies included a control group but were included in
this meta-analysis as no outcome data were reported for this
group (Sokhadze et al., 2009, 2016; Baruth et al., 2010). None of
the studies used subject or rater blinding, or an intent to treat
analysis. All used stimulation frequencies between 0.5 and 1Hz
and, except for Sokhadze et al. (2009) and Sokhadze et al. (2010),
all targeted the DLPFC bilaterally. These studies had a significant
combined effect size of−0.35 (95% CI:−0.67 to−0.03; z=−2.7;
p = 0.008). The Cochrane’s Q-test was significant (Q = 44.9,
p < 0.001), with an I2-value of 86.6% and T2 of 0.06. The
funnel plot and trim-and-fill analysis for this combined effect
size estimation were not suggestive of publication bias or missing
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FIGURE 3 | Effects of rTMS on repetitive and restricted behavior in controlled studies. (A) Forest-plot. Dots represent each study, with dot size reflecting study weight
in the model and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its confidence interval (narrow
interval) and its 95% prediction interval (wide interval). (B) Funnel-plot. There is evidence of significant publication bias. Square-shaped dots represent studies imputed
by trim-and-fill analysis.
studies (Figure 4) and the Egger statistic was not significant
(intercept=−10.4, 95% CI:−26.2 to 5.4; t =−1.6, p= 0.2).
Regarding controlled studies, Casanova et al. (2012) did not
report data on social behavior, and thus only four studies were
entered in the meta-analysis. Only Enticott et al. (2014) and
Ni et al. (2017), adopted sham-controlled designs, and only the
former adopted a randomized controlled double-blind design.
Regarding stimulation targets, Enticott et al. (2014) used a H-
coil to stimulate the DMPFC at 5Hz. Ni et al. (2017) used iTBS
to stimulate the DLPFC, which was the target stimulated in the
other two studies, albeit at low frequency (1Hz). Figure 5 shows
the forest plot of these studies, with a combined effect size of
−0.47 (95% CI: −0.98 to 0.04; although z = −2.93; p = 0.003),
a non-significant Cochrane’s Q-test (Q = 5.4, p = 0.1), I2-value
of 45% and T2 of 0.04. The funnel plot and trim-and-fill analysis
were suggestive of publication bias (Figure 5), with two missing
studies, but Egger statistic was not significant (intercept = −2.8,
95% CI: −6.6 to 0.9; t = −2.39.3, p = 0.1). Furthermore, one
study (Enticott et al., 2014) described follow up assessments
1 month after treatment, when differences between sham and
active rTMS remained significant (Hedges’ g = −1.38; 95% CI:
−2.27 to−0.57, p= 0.016).
Effects of rTMS on irritability and hyperactivity were
measured with the corresponding ABC subscales. Figure 6 shows
the forest plot of pre-post studies for hyperactivity, with a
significant combined effect size of −0.29 (95% CI: −0.45 to
−0.12; z = −4.2; p < 0.001), non-significant Cochrane’s Q-
test (Q = 11.3; p = 0.08), I2-value of 46.7% and T2 of 0.01.
The funnel plot and trim-and-fill analysis for this combined
effect size estimation were not suggestive of publication bias
or missing studies (Figure 6), with a non-significant Egger
statistic (intercept = −1.8, 95% CI: −9.1 to 5.5; t = −0.6,
p = 0.6). All 7 of these studies were by the same research group.
None of them was subject or rater-blinded, and all used low-
frequency rTMS to stimulate the DLPFC, either bilaterally or
unilaterally (see Table 2 for details). Only two controlled studies
reported the effects of TMS on hyperactivity, both by Sokhadze
and colleagues, one of which (Sokhadze et al., 2014b) found
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FIGURE 4 | Effects of rTMS on social behavior deficits in non-controlled studies. (A) Forest-plot. Dots represent each study, with dot size reflecting study weight in the
model and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its confidence interval (narrow interval)
and its 95% prediction interval (wide interval). (B) Funnel-plot.
no significant differences between active TMS and waiting-list
condition (Hedges’ g = −0.36, 95% CI: −0.91 to 0.18) and the
other (Sokhadze et al., 2014a) reporting a significant interaction
between treatment arm and time (Hedges’ g = −0.71, 95% CI:
−1.36 to−0.09).
Figure 7 shows the forest plot of pre-post studies regarding
irritability, excluding Sokhadze et al. (2017) who did not provide
data on this measure. Again, these 6 studies were all by the same
research group and all incurred in risk of bias due to lack of
blinding (see above and Table 2 for further details) A significant
combined effect size of −0.53 was found (95% CI: −0.93 to
−0.13; z = −3.4; p = 0.001) with a significant Cochrane’s Q-test
(Q = 30.8; p < 0.001), I2-value of 83.8% and T2 of 0.1. The
funnel plot and trim-and-fill analysis for this combined effect
size estimation were not suggestive of publication bias or missing
studies (Figure 7) and the Egger statistic was not significant
(intercept= 11.5, 95% CI:−11 to 33.9; t = 1.3, p= 0.3). Figure 8
shows the forest plot of controlled studies that assessed the effects
of TMS on Irritability, excluding Ni et al. (2017) and Sokhadze
et al. (2014b) who did not provide data on this outcome. From
these 3 studies, only Enticott et al. (2014) had a randomized,
sham-controlled, double-blind design, while the remaining two
compared active rTMS with wait-list condition (see above for
stimulation parameter details). Their combined effect size was
−0.3 (95% CI: −1.32 to 0.72; z = −1.3; p = 0.2), with a non-
significant Cochrane’s Q-test (Q = 3.3, p = 0.2), I2-value of
39.9% and T2 of 0.06. Funnel plot and Egger statistic were not
interpretable due to the low number of studies (data not shown).
Effects on Cognitive Function
Eleven studies assessed the effects of rTMS on cognitive
performance in ASD patients, eight of which were controlled
studies comparing active rTMS treatment with either waiting-
list controls (Sokhadze et al., 2009, 2012, 2014a,b; Baruth et al.,
2010; Casanova et al., 2012) or sham-rTMS (Fecteau et al.,
2011; Ni et al., 2017). The 3 remaining studies, comparing
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FIGURE 5 | Effects of rTMS on social behavior deficits in controlled studies. (A) Forest-plot. Dots represent each study, with dot size reflecting study weight in the
model and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its confidence interval (narrow interval)
and its 95% prediction interval (wide interval). (B) Funnel-plot. There is evidence of possible significant publication bias, with 2 imputed studies (square-shaped dots)
estimated by trim-and-fill analysis.
cognitive performance before and after rTMS, could not be
used for meta-analysis because a common cognitive domain
was not assessed in all of them (Sokhadze et al., 2010, 2016;
Abujadi et al., 2017). Most of these studies report performance
measures on a visual oddball-type task, which requires subjects
to respond (e.g., press a button), or omit a response, when
an infrequent stimulus appears within a series of frequent
standard stimuli, presented rapidly. This type of task loads
on several dimensions of executive control, namely attention
control, workingmemory, response inhibition, and ability to shift
between alternative response strategies (Huettel and McCarthy,
2004). Performance is conventionally described in terms of
reaction-time do target stimuli, omission errors (failing to
respond to the target), commission errors (responding to non-
targets), and total number of errors. Ni et al. (2017) and Abujadi
et al. (2017) used theWisconsin Card Sorting Test, a classical and
widely known neuropsychological test used to assess cognitive
set-shifting ability. Abujadi et al. (2017) additionally used the
Stroop color-word test, a classical interference control task,
while Fecteau et al. (2011) used the Boston Naming Test, a
widely used test of confrontational naming, to assess naming
skills.
Sokhadze et al. (2010, 2016) while reporting no change in
reaction time in oddball-type tasks after rTMS in their ASD
samples, did not provide details on the underlying data, and
meta-analysis was not conducted. Figure 9 shows the forest plot
of the 7 controlled studies assessing the effects of rTMS on
reaction time to target stimuli. All were by the same research
group except Ni et al. (2017), which was also the only that
used iTBS and a sham-treated control group. The remaining
studies all used low-frequency rTMS. All studies stimulated the
DLPFC bilaterally, with the exception of Sokhadze et al. (2009)
who only stimulated the left DLPFC. None of the seven studies
used subject or rater-blinding, and thus all were exposed to both
performance and detection bias. The combined effect size of
−0.08 was not significant (95% CI: −0.58 to 0.42; z = −0.4;
p = 0.7), with a significant Cochrane’s Q-test (Q = 17.66,
p = 0.007), I2-value of 66% and T2 of 0.2. The funnel plot and
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FIGURE 6 | Effects of rTMS on hyperactivity in non-controlled studies. (A) Forest-plot. Dots represent each study, with dot size reflecting study weight in the model
and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its confidence interval (narrow interval) and its
95% prediction interval (wide interval). (B) Funnel-plot.
trim-and-fill analysis were not suggestive of publication bias and
suggested no missing studies (Figure 9), and the Egger statistic
was not significant (intercept = 3.42; 95% CI: −6.74 to 13.31;
t = 0.9, p = 0.4). Figure 10 shows the forest plot of the same
controlled studies regarding the effects of rTMS on the number of
errors in either a visual oddball task or the Conner’s Continuous
Performance Test, excluding Fecteau et al. (2011) that did not
assess this cognitive domain. The combined effect size of−0.38
was significant (95% CI: −0.61 to −0.16; z = −4.2; p < 0.001),
with a non-significant Cochrane’s Q test (Q = 5.6, p = 0.5), I2-
value of 0% and T2 of 0. The funnel plot and trim-and-fill analysis
were suggestive of publication bias, with three missing studies
to the right of the adjusted combined effect size (Figure 10),
and an adjusted effect size of −0.3 (95% CI: −0.5 to −0.08).
Egger statistic was significant (intercept = −0.1.61; 95% CI:
−3.1 to −0.1; t = −2.6, p = 0.048). Non-controlled studies
reported consistent results, with Sokhadze et al. (2010) describing
a significant reduction in the total percentage of errors from 11
± 12.3 to 3.3 ± 3.2% (t = 2.4, p = 0.04), and the same group
showing a similar result (mean change in % total errors of−5.5±
14.04, t=−2.1, p= 0.047) in a later study (Sokhadze et al., 2016).
Other Effects
In a randomized, sham-controlled study, Enticott et al. (2014)
assessed the effects of deep rTMS on performance of a group
of tasks loading on theory of mind skills (Reading the Mind
in the Eyes Task and Animations Mentalizing Task). After 10
sessions of 5Hz rTMS, delivered bilaterally over the dorsomedial
prefrontal cortex at 100% of the motor threshold, no differences
in performance were found with regards to the sham control in
any of the tasks (respectively Hedges g = 0.5, 95% CI: −0.28
to 1.32; and Hedges’ g = 0.71, 95% CI: −0.08 to 1.54). In an
earlier study, the same group (Enticott et al., 2014) assessed the
effects of a single 1Hz rTMS session, delivered either to the
left primary motor cortex or the left supplementary motor area,
when compared to sham stimulation of the left primary motor
cortex. Clinical outcome measures were motor reaction time
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FIGURE 7 | Effects of rTMS on irritability in non-controlled studies. (A) Forest-plot. Dots represent each study, with dot size reflecting study weight in the model and
error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its confidence interval (narrow interval) and its
95% prediction interval (wide interval). (B) Funnel-plot.
FIGURE 8 | Forest-plot of controlled studies that assessed the effects of rTMS on irritability. Dots represent each study, with dot size reflecting study weight in the
model and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its confidence interval (narrow interval)
and its 95% prediction interval (wide interval).
to a stimulus and movement time, none of which showed any
significant changes after rTMS to either target.
Panerai et al. (2014) performed a series of small proof of
principle trials to assess the utility of rTMS for improving eye-
hand integration ability in adolescents with ASD and severe
cognitive delay. In the first of these trials the authors tested the
effects of several stimulation targets and parameters (1Hz rTMS,
8Hz rTMS and sham), one session of each over the left and
right premotor cortex, at 2-week intervals. The authors found
a significant effect of 8Hz rTMS over the left premotor cortex,
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FIGURE 9 | Effects of rTMS on reaction time during performance of executive control tasks, in controlled studies. (A) Forest-plot. Dots represent each study, with dot
size reflecting study weight in the model and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its
confidence interval (narrow interval) and its 95% prediction interval (wide interval). (B) Funnel-plot.
when compared both to sham and 1Hz rTMS. In the second
trial, each of the treatment conditions (1Hz rTMS, 8Hz rTMS or
sham) was applied over the left premotor cortex to three different
groups, for a total of 10 sessions over consecutive weekdays.
A significantly better performance was reported in the group
treated with 8Hz rTMS when compared to the other two groups.
The third trial used a complex design to assess long-lasting
effects of 8Hz rTMS: the authors found a significant effect when
compared to sham stimulation, but the effect only persisted for
1 h after treatment conclusion. In a final trial the authors report
long-lasting effects of 8Hz rTMS at 4 weeks follow-up, but only
when rTMS was combined with an eye-hand integration training
program, and not for rTMS alone or the training program
alone.
Case-Reports
Four case-reports, describing five patients successfully treated
with rTMS (three of them with deep rTMS) are summarized in
Tables 1–3.
Adverse Effects
No serious adverse effects were reported. On the whole, 19
patients reported transient discomfort, during or immediately
after rTMS. Facial discomfort during treatment was by far the
most common side-effect, especially in patients treated with
TBS (11 patients). While, overall, adverse effects seem to be
infrequent, a more accurate estimation of their true incidence
in treated patients was not possible due to the fact that many
reports omit any mention to adverse effects, and it is thus unclear
whether they did not occur or were simply under-reported.
DISCUSSION
Summary of Main Findings
Here we conducted a systematic review of the available literature
on the use of TMS to treat ASD. We found 23 studies describing
the effects of rTMS on ASD symptoms and ASD-related cognitive
deficits, 4 of which were case-reports, 7 were non-controlled
prospective intervention trials and the 12 were controlled clinical
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FIGURE 10 | Effects of rTMS on total number of errors during performance of executive control tasks. (A) Forest-plot. Dots represent each study, with dot size
reflecting study weight in the model and error bars indicating the effect size (with confidence interval). The lower line represents the combined effect size with its
confidence interval (narrow interval) and its 95% prediction interval (wide interval). (B) Funnel-plot. There is evidence of possible significant publication bias, with 3
imputed studies (square-shaped dots) estimated by trim-and-fill analysis.
trials. Most studies assessed the typical autistic syndrome dyad of
social interaction deficits and repetitive and stereotyped behavior.
In terms of cognitive function, most studies assessed executive
functioning using paradigms that load on response inhibition,
working memory, and flexibility.
Meta-analyses of these studies, conducted separately for
controlled and non-controlled studies, globally showed that
rTMS treatment results in a significant reduction of repetitive
behavior, with a medium-size effect size, but with evidence of
significant publication bias in both meta-analyses, tempering the
potential enthusiasm with this finding. The effects of rTMS on
social interaction deficits were less robust, with non-controlled
studies showing a small to medium effect size, albeit with
significant heterogeneity, while controlled studies, although with
a significant z-statistic suggesting a significant combined effect
size, had a 95% CI, estimated using the weighted variance
method, crossing the line of no-effect. This results from the
fact that the conventional z-distribution method underestimates
confidence interval width when the number of studies is small
and heterogeneity moderate or high, as in the case here (Sánchez-
Meca and Marín-Martínez, 2008). Moreover, there was evidence
for publication bias in the controlled studies meta-analysis.
Altogether, evidence for a significant effect of rTMS treatment
on social interaction deficits is thus modest and inconsistent,
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with a clear need for more robust evidence before a definitive
conclusion is reached. Similarly, evidence of significant effects
on hyperactivity or irritability is limited, with either small effect-
sizes, or significant heterogeneity that limits the interpretability
of combined effect-sizes.
With respect to the effects of rTMS on cognitive function,
available evidence suggests a positive effect on executive and
attentional control, with a reduction of the total number of
errors in specific oddball-type cognitive tests. The combined
effect size of these studies was of moderate magnitude, with no
evidence of heterogeneity, but significant evidence of publication
bias. In contrast, rTMS appears to have no significant effect
on reaction time, a correlate of the psychomotor slowness that
is characteristic of ASD. One sham-controlled study explicitly
studied the effects of deep rTMS on the ability to solve Theory
of Mind problems and found no significant improvement in this
complex cognitive skill after TMS (Enticott et al., 2011). Another
study assessed the effects of rTMS on eye-hand integration
ability and found a significant improvement in performance
of eye-hand integration tasks (Panerai et al., 2014). Finally,
Fecteau et al. (2011) found that low-frequency rTMS over
the left pars triangularis resulted in better performance of a
confrontational naming task than sham-stimulation or rTMS
over the homolateral pars opercularis. These are isolated proof-
of-concept studies that measured the effects of rTMS on specific
cognitive functions relevant in the context of ASD, but that did
not see any further developments to date.
The choice of stimulation parameters and targets for rTMS in
ASD treatment seems to follow a pattern whereby low-frequency
stimulation, with suppressive effects on cortical excitability, is
used for dorsolateral prefrontal targets while medial prefrontal
targets and other, non-prefrontal targets, are preferentially
stimulated with higher frequencies (5–10Hz), which facilitate
cortical excitability. In addition to safety concerns regarding the
use of TMS on a vulnerable population such as ASD patients,
the rationale invoked in studies using low-frequency rTMS to
target the DLPFC rests on the hypothesis of an elevated local
cortical excitation-to-inhibition ratio in ASD, and the underlying
theory of decreasedGABAergic dampening of cortical excitability
(Casanova et al., 2002; Oblak et al., 2010). However, both Abujadi
et al. (2017) and Ni et al. (2017) used iTBS (with predominantly
facilitatory effects) over the right DLPFC and obtained significant
improvements in executive cognitive function and, in one of the
studies (Abujadi et al., 2017), also in stereotyped and repetitive
behavior. In fact, there are arguments to support that iTBS
potentiates both cortical excitation and inhibition, the latter
through mechanisms that may differ from those involved in
low-frequency rTMS (Rossi et al., 2009; Abujadi et al., 2017; Ni
et al., 2017). On the other hand, studies targeting the DMPFC
justify their choice of high-frequency rTMS with the fact that this
brain-region has been related with processing of Theory of Mind
challenges, that could thus be enhanced if cortical excitability
of this area, and related networks, is increased (Enticott et al.,
2011). Similarly, other isolated studies have chosen other targets
according to the specific clinical outcome under study, generally
choosing to apply high-frequency rTMS under the rationale
that increasing cortical excitability in a particular area will
result in improved performance of the function that these areas
are believed to sustain (Fecteau et al., 2011; Enticott et al.,
2012; Panerai et al., 2014). With only few exceptions (Sokhadze
et al., 2009, 2010; Enticott et al., 2012; Panerai et al., 2014;
Abujadi et al., 2017; Gómez et al., 2017) most studies also resort
to stimulating cortical areas in both hemispheres, sometimes
using complex stimulation schedules, where one hemisphere is
stimulated first, then the other, and finally both in alternating
succession. However, with the exception of the results reported
by Enticott et al. (2012), the outcome of unilateral stimulation did
not seem to be inferior to that of equivalent studies using bilateral
targets.
Regarding stimulation protocols, there is also significant
variability between different studies. A distinctive feature for
most studies is the use of relatively conservative protocols, with
stimulus intensities below resting motor threshold, the use of low
frequencies within the range of high-frequency rTMS, and long
intervals between successive TMS sessions. This could reflect
fear of adverse effects, namely seizures, for which patients with
ASD are at higher risk (Rossi et al., 2009). Predominance of
such conservative protocols also makes results more difficult to
interpret, as in these conditions the effects of rTMS are much
more variable across individuals (Maeda et al., 2000).
Limitations
Overall, interpretation of the existing literature with respect to
the use of TMS for treatment of ASD is limited by concerns
regarding study quality. In addition to the rare use of adequate
control groups and control interventions, most studies did not
safeguard against performance and detection bias, as neither
subjects nor their caregivers were blinded with respect to
treatment status, the same applying to outcome evaluators. The
frequent use of parent- or caregiver-scored assessment scales,
rather than direct assessments of clinical effects with the patients
themselves, is also an important limitation and potential source
of measurement bias. Moreover, while dropouts and exclusion
of recruited individuals was a frequent occurrence, none of the
reviewed studies adopted an intent-to-treat analysis.
In fact, the overwhelming majority of the reviewed studies
showed one or both of two major methodological limitations: an
inadequate control group and an inadequate follow-up period.
For most dimensions of ASD core symptoms, a significant
proportion of existing studies were non-controlled trials, and
among controlled trials the vast majority compared outcome
in the active rTMS arm with outcome in a waiting-list group.
This means that placebo-effects, likely to be significant in an
intervention like rTMS, cannot be ruled out, and are indeed a
likely contributor for the observed effects. Only a very limited
number of studies actually compared active rTMS to sham-rTMS
(Fecteau et al., 2011; Enticott et al., 2012, 2014; Panerai et al.,
2014; Ni et al., 2017), two of which (Fecteau et al., 2011; Ni et al.,
2017) used a cross-over design, that is inferior to a classical sham-
controlled design as subjects are more likely to discriminate
between active and control interventions. Finally, several studies
opted to compare rTMS treatment between patients with ASD
and healthy individuals, which is not particularly informative for
clinical practice. The other major limitation of most studies is the
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absence of an adequate follow-up period after the last stimulation.
Only five studies assessed the stability of therapeutic gains 1
month or more after the end of treatment (Enticott et al., 2011,
2014; Panerai et al., 2014; Abujadi et al., 2017; Gómez et al., 2017),
with the majority of studies only measuring therapeutic effects
immediately after conclusion of rTMS. It is noteworthy that most
of these limitations had already been noted by Oberman et al.
(2016) in their review and, although we now have several more
studies, the same limitations remain pertinent and prominent
(Oberman et al., 2016). Furthermore, as of May 2018, a search of
clinical trials.gov found few active or recruiting studies assessing
the effects of TMS on various clinical symptoms dimensions
of ASD. Of these, most were open-label single-group studies,
or controlled but not blinded nor randomized, revealing an
ominous trend to perpetuate the limitations of previous studies
in the field.
Another unsettled issue is whether the effects of rTMS or
iTBS on ASD symptoms vary with patient age, patient gender, or
presence/absence of cognitive delay. Available studies, with the
notable exception of Anninos et al. (2016), exclusively recruited
adolescents or young adults, and most included a small number
of female subjects in the active treatment arm with no separate
reporting of the outcome measures for males and females. The
same applies for the possible effects of co-morbid cognitive delay,
with studies either excluding patients with cognitive delay or
including amix of subjects with andwithout cognitive delay (with
the exception of Panerai et al., 2014, who only recruited patients
with severe cognitive disability).
CONCLUSIONS
In summary, there is limited preliminary evidence for a positive
effect of rTMS on stereotyped and repetitive behavior, one of
the core symptom dimensions of ASD, and even more limited
evidence that rTMS has a positive effect on social behavior and
some aspects of executive function. The significance of these
findings is limited by concerns regarding the heterogeneity of
data, as well as publication bias and the quality of the original
studies. Critically, it remains unknown whether any such positive
effects are lasting enough to be clinically useful. It is also
unclear which stimulation parameters, targets and schedules
offer the best opportunities for improvement or are most cost-
effective. Moreover, it is unlikely that TMS will be able to achieve
significant improvements in all symptom domains of ASD,
with more limited effects likely to be found on more complex
dimensions of behavior such as social behavior or Theory ofMind
reasoning. Notwithstanding these limitations of the available
studies, there seems to be reasonable evidence that clinical use
of rTMS in patients with ASD is safe and well tolerated. In fact,
there are no reports of serious adverse effects, and those that
were reported were for the most part well tolerated and transient.
Thus, there is a clear need for further, better-designed studies on
the use of rTMS to treat ASD. To enhance the currently available
data, future studies must be randomized, sham-controlled and
double-blind, and should include adequate periods of follow-up
after the end of treatment.
Our main, inevitable conclusion is that, at present, rTMS
cannot be recommended as a viable or evidence-based treatment
for ASD. Clear evidence of both short- and long-term efficacy is
lacking, and it remains unclear whether the preliminary, limited
evidence of a clinical effect is valid to all patient subgroups
alike or which patient profile is most likely to benefit from this
treatment.
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